Innowl
Category: AI in Healthcare
Korean healthcare AI startup building RNA transcriptome-based precision diagnostics for atopic dermatitis using microneedle patches and AI endotype classification. Innowl was founded in 2025. The company is led by Jin-Muk Lim. Based in Seoul, South Korea. Team size: 1-10. Latest round: Seed. Key investors include CNTTech, DB Capital.
- Founded
- 2025
- Headquarters
- Seoul, South Korea
- Team size
- 1-10
Value proposition
Combines minimally invasive RNA-seq skin sampling with AI-powered endotype classification to enable objective, personalized diagnosis and treatment response prediction for atopic dermatitis, replacing burdensome blood draws/biopsies.
Products and solutions
Atopic Dermatitis AI Diagnosis platform, Immune Endotype Classification (Th2, Th17, barrier dysfunction), Treatment Response Prediction / CDSS module, planned SaMD (Software as a Medical Device) platform
Unique value
Minimally invasive microneedle-based RNA transcriptome analysis paired with AI modeling for patient-level molecular subtype classification, rather than relying on symptoms or imaging alone.
Target customer
Dermatology clinics, university hospitals, pharmaceutical companies, and research institutions
Industries served
Healthcare, Dermatology, Precision Medicine, BioHealth AI
Technology advantage
Proprietary RNA analysis algorithms and AI platform; partners with specialized firms for microneedle manufacturing/application to focus internal resources on core AI/bioinformatics IP.
How they differentiate
Focus on molecular/RNA-based diagnosis rather than image- or symptom-based diagnosis; minimally invasive patient-friendly sampling method (microneedle patches) suited for pediatric patients
Main competitors
VIENCE (AI biomedical image analysis), Soombit.AI (AI radiology), general AI-in-dermatology diagnostic tools (e.g. DermAssist-class imaging AI) as adjacent competitive approaches
Key partnerships
Running clinical trials with major university hospitals across Korea, partnerships with specialized microneedle manufacturing/application technology firms, plans to join Korea's TIPS program
Major milestones
Closed seed funding (Feb 2026) from CNTTech and DB Capital, running clinical trials with major Korean university hospitals, targeting diagnostic kit market launch around 2028, plans to join Korea's TIPS program
Growth metrics
6 employees (as of 2026-06; National Pension / THE VC); ~4 hires in prior 12 months, 0 exits
Market positioning
Early-stage precision diagnostics company aiming to set the standard for atopic dermatitis subtype classification in Korea, with plans to expand into drug development collaborations
Geographic focus
South Korea, with ambitions to expand to pharma/research collaborations
About Jin-Muk Lim
Bioinformatics/genomics/precision medicine researcher background (Google Scholar profile lists Bioinformatics, Genomics, Drug Discovery, Precision Medicine as research areas).
Latest news about Innowl
More AI in Healthcare companies
Official website: https://innowl.io/en